Showing results (11-20 of 25) with videos related to
Sort By:
Pageof 3
JCO Clinical Cancer Informatics|July 23, 2021
Model Development of CDK4/6 Predicted Efficacy in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast CancerJeremy Mason, Yutao Gong, Laleh Amiri-Kordestani, et al.Nature Reviews. Drug Discovery|June 21, 2023
Trends in the approval of cancer therapies by the FDA in the twenty-first centuryEmma C Scott, Andrea C Baines, Yutao Gong, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2021
Response Rate, Event-Free Survival, and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia: US Food and Drug Administration Trial-Level and Patient-Level AnalysesKelly J Norsworthy, Xin Gao, Chia-Wen Ko, et al.The Oncologist|July 1, 2021
Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public HealthElaine Chang, Lorraine Pelosof, Steven Lemery, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 23, 2020
FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial CarcinomaElaine Chang, Chana Weinstock, Lijun Zhang, et al.The Oncologist|October 5, 2020
FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian CancerShaily Arora, Sanjeeve Balasubramaniam, Hui Zhang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 29, 2021
The FDA Oncology Center of Excellence Scientific Collaborative: Charting a Course for Applied Regulatory Science Research in OncologyJulie A Schneider, Yutao Gong, Kirsten B Goldberg, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2020
FDA Approval Summary: Tucatinib for the Treatment of Patients with Advanced or Metastatic HER2-positive Breast CancerMirat Shah, Suparna Wedam, Joyce Cheng, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 2020
FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1Preeti Narayan, Sakar Wahby, Jennifer J Gao, et al.The Lancet. Oncology|July 26, 2021
Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trialsJaleh Fallah, Lijun Zhang, Anup Amatya, et al.Pageof 3